Featured Article
The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview
To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.
Latest Features
The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview
To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.
Managing Heart Failure: Improving Quality of Life and Preventing Excerbations
Heart failure is the number 1 reason for patient re-admittance to acute-care facilities according to the American Heart Association.
Preventing Heart Failure One Risk Factor at a Time
Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.
Hope for Heart Failure in Thyroid Hormone Therapy
Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.
Premature Ventricle Contractions in Heart Failure: A Closer Examination
A primer on premature ventricle contractions with commentary from 2 arrhythmic/heart failure experts.
ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD
While ARVD/C management has greatly improved, more precautions—particularly in genetic testing and exercise—need to be taken.
Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"
Drs Tauras and Patel from Montefiore Medical Center in the Bronx, New York weigh in on what the new heart failure therapeutic guidelines mean for practicing clinicians.
Managing Cardiovascular Complications of Oncology Treatment
Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.
Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure
Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.
Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD
Exercise's potential positive effects on cardiovascular disease and heart failure may be possible regardless of frequency and time of initiation.
Latest News
LVAD in Heart Failure Linked to Improved Glycemic Control
HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.
FDA Fast Track Designation Granted to Praliciguat for HFpEF
The Company is currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial; they expect to enroll 175 in total.
Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD
Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.
Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy
Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.
Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes
Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.
Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic
To date, there have been no reports of any adverse events related to this recall.
Emphysema Associated With Worse Outcomes in Heart Failure
After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.
Entresto Initiation Soon After Acute HF Episode Safe in HFrEF Patients
The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart failure episode when treatment was initiated either pre-discharge or post-discharge.
New Clinical Trial Targets Gut Microbiota in Heart Failure
GutHeart, a new ongoing clinical trial, will investigate the potential benefits of treating gut bacteria in heart failure.
The Cardiology Advisor Articles
- ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults
- No Apparent Short-Term Cancer Risk From Recalled Valsartan
- FDA Approves Device to Treat Acute Coronary Artery Perforations
- Oral Contraceptives Associated With Ventricular Repolarization Alterations
- SAVR vs TAVR: Adverse Outcomes Risk in Aortic Stenosis
- Can Chaplains Guide Clinical Decision Making? An Ethical Assessment of Spirituality in the Exam Room
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- CHEST Releases Guideline for Antithrombotic Therapy in Atrial Fibrillation
- ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults
- CHA2DS2-VASc Scores Drive Clinical Outcomes in Atrial Fibrillation, Flutter
- Central Obesity Not Predictive of Cardiovascular Events in Older Men
- Revisiting the Clinical Utility of High Sensitivity Cardiac Troponin I Assays
- PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- Rapid Cardiac Magnetic Resonance With Contrast Feasible in Developing World